News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
706,176 Results
Type
Article (42645)
Company Profile (265)
Press Release (663266)
Multimedia
Podcasts (55)
Webinars (12)
Section
Business (205541)
Career Advice (2057)
Deals (35597)
Drug Delivery (98)
Drug Development (82294)
Employer Resources (172)
FDA (16289)
Job Trends (15017)
News (348026)
Policy (32805)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (8)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2645)
Accelerated approval (5)
Adcomms (22)
Allergies (85)
Alliances (49998)
ALS (92)
Alzheimer's disease (1405)
Antibody-drug conjugate (ADC) (135)
Approvals (16287)
Artificial intelligence (257)
Autoimmune disease (23)
Automation (16)
Bankruptcy (361)
Best Places to Work (11751)
BIOSECURE Act (20)
Biosimilars (105)
Biotechnology (190)
Bladder cancer (78)
Brain cancer (28)
Breast cancer (281)
Cancer (2282)
Cardiovascular disease (175)
Career advice (1717)
Career pathing (31)
CAR-T (150)
Cell therapy (424)
Cervical cancer (20)
Clinical research (66806)
Collaboration (851)
Compensation (524)
Complete response letters (21)
COVID-19 (2648)
CRISPR (42)
C-suite (241)
Cystic fibrosis (104)
Data (2202)
Decentralized trials (2)
Denatured (19)
Depression (48)
Diabetes (269)
Diagnostics (6404)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (122)
Drug pricing (101)
Drug shortages (25)
Duchenne muscular dystrophy (94)
Earnings (86711)
Editorial (40)
Employer branding (21)
Employer resources (146)
Events (113180)
Executive appointments (723)
FDA (17538)
Featured Employer (51)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (761)
Gene editing (106)
Generative AI (20)
Gene therapy (309)
GLP-1 (740)
Government (4464)
Grass and pollen (4)
Guidances (54)
Healthcare (18973)
Huntington's disease (23)
IgA nephropathy (28)
Immunology and inflammation (120)
Indications (29)
Infectious disease (2794)
Inflammatory bowel disease (138)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (97)
Interviews (321)
IPO (16554)
IRA (41)
Job creations (3684)
Job search strategy (1458)
Kidney cancer (10)
Labor market (38)
Layoffs (473)
Leadership (16)
Legal (7975)
Liver cancer (75)
Lung cancer (323)
Lymphoma (152)
Machine learning (7)
Management (58)
Manufacturing (310)
MASH (68)
Medical device (13444)
Medtech (13449)
Mergers & acquisitions (19585)
Metabolic disorders (697)
Multiple sclerosis (82)
NASH (17)
Neurodegenerative disease (97)
Neuropsychiatric disorders (30)
Neuroscience (1963)
NextGen: Class of 2025 (6593)
Non-profit (4552)
Northern California (2656)
Now hiring (39)
Obesity (372)
Opinion (217)
Ovarian cancer (77)
Pain (89)
Pancreatic cancer (86)
Parkinson's disease (156)
Partnered (21)
Patents (232)
Patient recruitment (110)
Peanut (46)
People (57702)
Pharmaceutical (66)
Pharmacy benefit managers (18)
Phase I (20866)
Phase II (29449)
Phase III (21873)
Pipeline (1187)
Policy (144)
Postmarket research (2605)
Preclinical (8942)
Press Release (67)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (256)
Rare diseases (390)
Real estate (5956)
Recruiting (65)
Regulatory (22438)
Reports (46)
Research institute (2389)
Resumes & cover letters (355)
Rett syndrome (5)
RNA editing (5)
RSV (44)
Schizophrenia (71)
Series A (133)
Series B (87)
Service/supplier (11)
Sickle cell disease (53)
Southern California (2287)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3664)
State (2)
Stomach cancer (16)
Supply chain (69)
Tariffs (40)
The Weekly (34)
United States (23033)
Vaccines (710)
Venture capitalists (41)
Weight loss (244)
Women's health (35)
Worklife (15)
Date
Today (211)
Last 7 days (865)
Last 30 days (2708)
Last 365 days (33175)
2025 (10536)
2024 (35576)
2023 (40463)
2022 (51512)
2021 (56105)
2020 (54474)
2019 (46936)
2018 (35375)
2017 (32518)
2016 (31946)
2015 (38003)
2014 (31699)
2013 (26745)
2012 (28963)
2011 (29617)
2010 (27693)
Location
Africa (744)
Alabama (53)
Alaska (7)
Arizona (234)
Arkansas (13)
Asia (38461)
Australia (6331)
California (6083)
Canada (2006)
China (529)
Colorado (266)
Connecticut (275)
Delaware (146)
Europe (83290)
Florida (902)
Georgia (203)
Idaho (57)
Illinois (541)
India (25)
Indiana (309)
Iowa (11)
Japan (157)
Kansas (105)
Kentucky (23)
Louisiana (11)
Maine (62)
Maryland (887)
Massachusetts (4570)
Michigan (216)
Minnesota (392)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (64)
New Jersey (1716)
New Mexico (29)
New York (1737)
North Carolina (962)
North Dakota (8)
Northern California (2656)
Ohio (202)
Oklahoma (14)
Oregon (36)
Pennsylvania (1373)
Puerto Rico (12)
Rhode Island (33)
South America (1120)
South Carolina (22)
South Dakota (1)
Southern California (2287)
Tennessee (102)
Texas (905)
Utah (181)
Virginia (143)
Washington D.C. (63)
Washington State (552)
West Virginia (3)
Wisconsin (54)
706,176 Results for "promis neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
April 1, 2025
·
14 min read
Press Releases
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
March 11, 2025
·
1 min read
Press Releases
ProMIS Neurosciences Issues Letter to Shareholders
January 14, 2025
·
9 min read
Press Releases
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
·
1 min read
Press Releases
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
March 13, 2025
·
8 min read
Business
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Inc. announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
10 min read
Press Releases
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
March 25, 2025
·
9 min read
Press Releases
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
February 26, 2025
·
8 min read
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
ProMIS Neurosciences, Inc. announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences’ lead product candidate, PMN310, for the treatment of Alzheimer’s disease .
March 11, 2024
·
5 min read
Genetown
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
ProMIS Neurosciences Inc. today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will present at the 2024 BIO CEO & Investor Conference, taking place in-person in New York, NY on February 26-27, 2024.
February 22, 2024
·
1 min read
1 of 70,618
Next
